the Possible Effect of the Antiviral Inhibitors for Treatment of Hepatitis C Virus Infection in Cardiac Function
NCT ID: NCT03166943
Last Updated: 2020-01-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
130 participants
INTERVENTIONAL
2017-05-10
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination
NCT03490097
Quality of Life in Patients With HCV Related Liver Cirrhosis Before and After Direct Acting Antiviral Drugs
NCT03897608
Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients With Chronic Hepatitis C
NCT03402165
Neuropsychiatric Adverse Effects in Patients With Chronic Hepatitis C Treated by Direct Acting Antiviral Drugs
NCT03268317
Pattern of Skin Manifestations in Chronic Hepatitis c Virus Patients Before and After Direct Acting Anti Viral Drugs
NCT03170076
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Assessment of diastolic function by echocardiography to 30 hepatitis C virus infected patients who will not receive antiviral treatment, by left atrium volume , mitral inflow pattern , tissue doppler annular early and late diastolic velocities .
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
study group
Systolic function by echocardiography to100 Hepatitis C virus infected patients on continuous regimen ( sofosbuvir and daclatasvir )
Systolic function by echocardiography
Echocardiography for evaluation of systolic function:
* by biplane Simpson's method.
* by speckle tracking:
Control group
Diastolic function by echocardiography age and sex matched group of 30 patients with Hepatitis C virus who did not receive antiviral treatment ( sofosbuvir and daclatasvir )
Diastolic function by echocardiography
Echocardiography for evaluation of diastolic function:
* Left atrial Volume
* Mitral Inflow Patterns
* Pulsed wave Doppler
* Mitral inflow patterns include normal, impaired left ventricular relaxation, pseudonormal, and restrictive left ventricular filling patterns.
* Tissue Doppler Annular Early and Late Diastolic Velocities
* Pulsed wave tissue doppler imaging
* Primary measurements include the systolic , early diastolic, and late diastolic velocities.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Systolic function by echocardiography
Echocardiography for evaluation of systolic function:
* by biplane Simpson's method.
* by speckle tracking:
Diastolic function by echocardiography
Echocardiography for evaluation of diastolic function:
* Left atrial Volume
* Mitral Inflow Patterns
* Pulsed wave Doppler
* Mitral inflow patterns include normal, impaired left ventricular relaxation, pseudonormal, and restrictive left ventricular filling patterns.
* Tissue Doppler Annular Early and Late Diastolic Velocities
* Pulsed wave tissue doppler imaging
* Primary measurements include the systolic , early diastolic, and late diastolic velocities.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. normal baseline trans thoracic echocardiography
3. normal Electrocardiography
Exclusion Criteria
3- Patients with underlying any structural heart disease.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rania Reda Yacoub
principal investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Medicine
Asyut, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Rania Yacoub
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SSD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.